{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pyelonephritis-acute/prescribing-information/co-amoxiclav/","result":{"pageContext":{"chapter":{"id":"d385ea3c-fa24-5d51-8bf6-b1372c9fdf3c","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav","depth":2,"htmlHeader":"<!-- begin field c77324c8-ae57-42ce-a95d-6696ba47e5b2 --><h2>Co-amoxiclav</h2><!-- end field c77324c8-ae57-42ce-a95d-6696ba47e5b2 -->","summary":"","htmlStringContent":"<!-- begin item f83eb5ea-4a53-48e3-b262-2061fd2a62f0 --><!-- end item f83eb5ea-4a53-48e3-b262-2061fd2a62f0 -->","topic":{"id":"1ee909c1-6785-5b3a-a71f-c675db878f51","topicId":"44207967-66bd-4750-aa84-8d9a53c85df0","topicName":"Pyelonephritis - acute","slug":"pyelonephritis-acute","lastRevised":"Last revised in November 2020","chapters":[{"id":"02ed8486-e946-512b-82a2-668a9ff16030","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"46426ef8-dbce-5314-8014-895736033f59","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e0c98a4b-654e-5b3d-acbe-7af83e06b09e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d957e39c-6b0e-5ab2-b109-25b3d89f2a69","slug":"changes","fullItemName":"Changes"},{"id":"ac7d383b-749f-5a71-b1a3-64b8ee85c6e4","slug":"update","fullItemName":"Update"}]},{"id":"d8333a3b-c658-5cb9-8d52-f4731cb7591a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"82a178c6-fb1b-55a0-8fff-db47a9a4e56f","slug":"goals","fullItemName":"Goals"},{"id":"528ddc23-f69e-558e-a643-3efdf3ed0c46","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"251eeb06-8579-5cc4-8e1a-95f1d66519b7","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f66a975d-d6fb-5db8-9b28-8efc292c4f13","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b5e9e7df-f433-574c-9008-725e03502836","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c0a10e02-7199-5bc4-858a-f5b264b68ca3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"86ae3b5d-e5ac-595b-9ce2-6bd39b36e14d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"56a59908-ef99-57a5-94c0-91567fd0c3c3","slug":"definition","fullItemName":"Definition"},{"id":"ec53872e-9c88-566c-bda0-5c8be69f09ba","slug":"causes","fullItemName":"Causes"},{"id":"73f19a3b-6441-55c5-81ba-0912f3b42a15","slug":"complications","fullItemName":"Complications"},{"id":"17fd8038-ffd8-57e6-aa5e-f86def547e29","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"235cbfdb-ded5-56f1-8b79-6e33631422d9","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ca15553-84c0-5297-abd9-5141ab1dbec6","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ede39de9-ed86-5d54-8a0d-82bf548356a4","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"2c226c8f-c4ef-59ed-828e-590f38c1719c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3f5167b2-e2ea-5d21-93ef-3ed426750dea","fullItemName":"Management","slug":"management","subChapters":[{"id":"30a86df1-8159-5bcc-9187-aa647071eeab","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"db7647fb-c954-543c-ac60-d09f69832f7e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"93430c57-39bc-5b8b-b176-44cccba23928","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"d385ea3c-fa24-5d51-8bf6-b1372c9fdf3c","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"f429e0c9-ab9b-5885-b171-ea841f15722e","slug":"cefalexin","fullItemName":"Cefalexin"},{"id":"df1e11c6-9e97-5899-b2b9-0eac5877ab4c","slug":"trimethoprim","fullItemName":"Trimethoprim"}]},{"id":"936e6198-43d8-5e72-be82-c2c59705ea07","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2b045a54-20ef-5b6e-8003-81b3052b42a8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bf21ee38-5a2a-5700-bfd5-24b5084b8cbf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4a868f34-40b1-5196-97ec-2b8334024394","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5d08cf27-dc02-5eea-b5c3-b6308f0d1374","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"11dfcefc-cdc3-5c3f-aeea-da5c0be2ebaa","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5cc5db18-4c4f-5e6e-9169-72968b0e3705","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f7685686-568f-5174-afd7-a7778a4f2716","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"db7647fb-c954-543c-ac60-d09f69832f7e","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"c4460246-9901-521e-962a-33072521dc3c","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 16e8b836-2304-40f0-8b90-ad2d8474088f --><h3>Contraindications and cautions</h3><!-- end field 16e8b836-2304-40f0-8b90-ad2d8474088f -->","summary":"","htmlStringContent":"<!-- begin item 59b584b6-4ed5-4912-bade-e8f71bc6868f --><!-- begin field 02376297-9c41-4147-855c-effa24f2f54a --><ul><li><strong>Do not prescribe co-amoxiclav in people with:</strong><ul><li>A <em>true </em>penicillin allergy — allergic reactions to penicillins occur in 1–10% of exposed individuals; anaphylactic reactions occur in fewer than 0.05% of treated patients.</li><li>Gastrointestinal adverse effects alone (for example nausea, vomiting, or diarrhoea) do <em>not </em>constitute an allergy to penicillin. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a> for more information.</li><li>A history of co-amoxiclav- or penicillin-associated jaundice or hepatic dysfunction.</li></ul></li><li><strong>Prescribe co-amoxiclav with caution in people with:</strong><ul><li>A hypersensitivity to cephalosporins — there is some evidence of partial cross-allergenicity. </li><li>Hepatic impairment — monitor closely.</li><li>Chronic kidney disease (CKD) — reduce the dose if the estimated glomerular filtration rate (eGFR) is 30 mL/minute/1.73 m<sup>2</sup> or less.</li><li>Acute lymphocytic leukaemia, chronic lymphocytic leukaemia, cytomegalovirus infection, glandular fever — increased risk of erythematous rashes.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">BNF 76, 2018</a>]</p><!-- end field 02376297-9c41-4147-855c-effa24f2f54a --><!-- end item 59b584b6-4ed5-4912-bade-e8f71bc6868f -->","subChapters":[]},{"id":"3076ddc9-501d-5cb1-b4d4-d1a12f7f7b09","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 5e354d83-9939-49ff-9e74-fc1ea21857af --><h3>Adverse effects </h3><!-- end field 5e354d83-9939-49ff-9e74-fc1ea21857af -->","summary":"","htmlStringContent":"<!-- begin item 503aeccb-2a26-4100-9e08-bcd64cc1f176 --><!-- begin field 712efa15-9942-42c8-ad18-ceda1572e3ac --><ul><li><strong>Gastrointestinal </strong>— nausea and vomiting (common), vomiting (very common).<ul><li><strong>Very rarely: </strong>antibiotic associated colitis.</li></ul></li><li><strong>Nervous system</strong> — headache, dizziness (uncommon).</li><li><strong>Skin</strong> — skin rash, urticaria and pruritus (uncommon), drug reaction with eosinophilia and systemic symptoms (DRESS) (frequency unknown).<ul><li><strong>Very rarely:</strong> erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous and exfoliative dermatitis and acute generalised exanthematous pustulosis.</li></ul></li><li><strong>Other rare, or very rare adverse effects include:</strong><ul><li>Hepatitis, cholestatic jaundice.</li><li>Hyperactivity, convulsions.</li><li>Hypersensitivity reactions (serious and occasionally fatal).  </li><li>Interstitial nephritis.</li><li>Leukopenia, thrombocytopenia, haemolytic anaemia.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">BNF 76, 2018</a>]</p><!-- end field 712efa15-9942-42c8-ad18-ceda1572e3ac --><!-- end item 503aeccb-2a26-4100-9e08-bcd64cc1f176 -->","subChapters":[]},{"id":"df0a2930-b20b-5d51-a122-962cbdc35269","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field dc421735-8d52-4dd2-9c24-a75a00d4132c --><h3>Drug interactions</h3><!-- end field dc421735-8d52-4dd2-9c24-a75a00d4132c -->","summary":"","htmlStringContent":"<!-- begin item c2832dd8-0edc-4ad9-aaac-a75a00d41208 --><!-- begin field 64382855-6747-4c04-9351-a75a00d4132c --><ul><li><strong>Allopurinol </strong>— concomitant use of allopurinol and amoxicillin may increase the incidence of skin rashes.</li><li><strong>Methotrexate </strong>— co-amoxiclav may reduce methotrexate clearance, causing an increased risk of toxicity.<ul><li>Monitor methotrexate levels more closely. One recommendation is to carry out twice weekly platelet and white cell counts for 2 weeks initially, with the measurement of methotrexate levels if toxicity is suspected.</li></ul></li><li><strong>Mycophenolate mofitil</strong> — reduction in the level of active metabolite may occur when given with co-amoxiclav.</li><li><strong>Oral anticoagulants (warfarin, phenindione) </strong>— prolongation of prothrombin time has been reported in people taking penicillins and warfarin concurrently.<ul><li>Monitor the prothrombin time or international normalized ratio (INR) more closely with the addition or withdrawal of a penicillin. Adjustment of the anticoagulant dose may be necessary.</li></ul></li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of co-amoxiclav.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>. </li></ul></li><li><strong>Probenecid </strong>— concomitant administration may result in increased levels of amoxicillin, but not clavulanic acid.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">FSRH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">BNF 76, 2018</a>] </p><!-- end field 64382855-6747-4c04-9351-a75a00d4132c --><!-- end item c2832dd8-0edc-4ad9-aaac-a75a00d41208 -->","subChapters":[]},{"id":"f6d59e8c-8f32-581e-8349-8e8668a6abc6","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 3a168bd3-02e8-4762-b579-a75a00d42348 --><h3>Pregnancy and breastfeeding</h3><!-- end field 3a168bd3-02e8-4762-b579-a75a00d42348 -->","summary":"","htmlStringContent":"<!-- begin item 46b744d3-6798-4b9c-9bac-a75a00d4239c --><!-- begin field 4bf62e99-3222-46f2-89d5-a75a00d42348 --><h4>Pregnancy</h4><ul><li>Co-amoxiclav is not known to be harmful in pregnancy.</li></ul><h4>Breastfeeding</h4><ul><li>Trace amounts of co-amoxiclav are found in breastmilk — it is not known to be harmful to breastfed children.<ul><li>Penicillins (and cephalosporins) are the antibiotics of choice in women who are breastfeeding.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">Kearney, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">BNF 76, 2018</a>]</p><!-- end field 4bf62e99-3222-46f2-89d5-a75a00d42348 --><!-- end item 46b744d3-6798-4b9c-9bac-a75a00d4239c -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}